Andy Boyer joins Teva exodus; Achaogen shuffles executive lineup
→ Teva’s US chief Andy Boyer has resigned and is leaving the company at the end of Q1 next year, according to Wells Fargo’s David Marris. It has been a turbulent week at the Israeli generics business, as new CEO Kåre Schultz unveiled a massive reorganization plan Thursday, which involves axing 14,000 workers, shuttering R&D and manufacturing facilities and radically paring down $3 billion in costs globally. In a signal of the intense fallout, on Wednesday, former chairman and interim CEO Yitzhak Peterburg abruptly resigned with immediate effect.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.